AeroLeads people directory · profile
Robert Discordia, Phd Email & Phone Number
Co-Founder, President and CEO
at
EQUULUS Therapeutics
1 work email found
@juno.com
5 phones found area 609, 732, and 212
LinkedIn matched
✓ Verified Jun 2026
4 data sources
Profile completeness 100%
Current company
Role
Co-Founder, President and CEO
Location
Charlotte, North Carolina, United States
Company size
Who is Robert Discordia, Phd? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Robert Discordia, Phd is listed as Co-Founder, President and CEO at EQUULUS Therapeutics, a company with 2 employees, based in Charlotte, North Carolina, United States. AeroLeads shows a work email signal at juno.com, phone signal with area code 609, 732, 212, and a matched LinkedIn profile for Robert Discordia, Phd.
Robert Discordia, Phd previously worked as Co-Founder, President & CEO at Equulus Therapeutics and Chief Scientific Officer at Caamtech. Robert Discordia, Phd holds Post Doctoral, Organic Chemistry from Scripps Research.
Company email context
Email format at EQUULUS Therapeutics
This section adds company-level context without repeating Robert Discordia, Phd's masked contact details.
*@juno.com
68% confidence
AeroLeads found 1 current-domain work email signal for Robert Discordia, Phd. Compare company email patterns before reaching out.
Profile bio
About Robert Discordia, Phd
Biotech Drug Development Strategist & Leader with success designing and executing operational and strategic growth initiatives. Design, build and lead R&D and advance discovery compounds to achieve "first-in-human dosing" in record times and dramatically lower costs. Senior team member active in originating and managing fundraising efforts and driving high-profile negotiations.Therapeutic area development agnostic with significant experience in development of Oncology, Immunooncology, Immunology, Inflammation, Fibrosis, CNS, Neurology, and Anti-viral.Pharmaceutical successes at AVANZARX, CORBUS, and BRISTOL MYERS SQUIBB include:§ PROGRAM-CENTRIC LIQUIDITY THESIS / VIRTUAL MODEL (Avanzarx): Created model to discover/develop therapeutic assets exclusively for established pharma providing high IRR using total virtual biotech model relying on external service providers (no fixed asset costs).§ PRE-CLINICAL DEVELOPMENT MODEL (Corbus): Implemented integrated development model for pre-clinical assets to achieve first human dose in < 1 year and reduce overall cost of phase by 35% from prior model.§ VARIABLIZATION OF API MANUFACTURING, 2017 (BMS): Led corporate-level transformation delivering $Multi-TenMillion in direct, cost avoidance, and product cost reduction savings.§ SUPPLIER CONSOLIDATION / RENEGOTIATION (BMS): Consolidated manufacturing supplier network and renegotiated supply contracts delivering $Multi-TenMillion savings - 7.0% reduction.§ RECOGNITION: - Conference Keynote Speaker/Presenter - 45+ Peer Reviewed Articles - 17 Patents & Applications - Small Molecules - Oligopeptides & Other Non-Traditional Small Molecules - Antibody Drug Conjugates - Vitamin Drug Conjugates - Traditional & Non-Traditional Formulation Approaches - CMC Expert - In/Out Licensing - Intellectual Property/Patents - Global External Suppliers in CRO/CMO/CDMO Industry - Outsourcing for Virtual & Semi-Virtual Biotechs and Established Pharma
Listed skills include R&D, Pharmaceutical Industry, Technology Transfer, Drug Development, and 37 others.
Current workplace
Robert Discordia, Phd's current company
Company context helps verify the profile and gives searchers a useful next step.
Equulus Therapeutics
8 roles
Robert Discordia, Phd work experience
A career timeline built from the work history available for this profile.
Co-Founder, President & Ceo
Current
Oct 2023 - Present
Chief Scientific Officer
Chief Scientific Officer responsible for pharmaceutical discovery and development. Specific achievements subject to Confidentiality Agreement.
Dec 2021 - Jun 2023
Co-Founder, President And Chief Executive Officer
Avanzarx
Configured company with innovative structure to discover/develop therapeutic assets using licensed technology from U. of Maryland School of Medicine (Prof. Sergei Atamas, MD, PhD) targeting immune system “regulatory hubs” controlling multiple pathways and cell types implicated in fibrogenesis. Selected AVZ-1001 as first pre-clinical asset.CORPORATE.
Dec 2020 - May 2022
Chief Operating Officer & Head, Pharmaceutical Development
Took charge to rapidly advance CMC development of lenabasum, delayed in deference to starting phase-III studies. Led efforts to set and operationalize organizational vision and strategy transforming 165-employee company. Redesigned internal operations and organization structure. Directed 65 reports to deliver pre-commercial company-wide operations and.
May 2018 - Nov 2020
Executive Director, Global Business Operations For Global Product Development And Supply
Led 55 employees across 7 global sites to manage external suppliers in support of Global Manufacturing & Supply (Commercial Manufacturing) and Global Pharmaceutical Development (Pre-Clinical to Launch). Controlled annual direct/indirect spend of $700M.DEVELOPMENT & SUPPLY (GPS) BUSINESS OPERATIONS LEADERSHIP: Directed support for External & Internal.
Aug 2013 - Apr 2018
Group Director & Head, External Partner Management, Pharmaceutical Development
Developed strategy and sourced all pre-clinical and clinical small molecule intermediates and APIs, formulation development and drug product manufacturing, analytical, and associated development services. Increased overall productivity 60%.ASIA SOURCING STRATEGY: Devised, developed, and implemented Asia sourcing strategy. Migrated significant portions of.
Oct 2007 - Aug 2013
Director Process Development
Led 4 major programs between 2000 and 2009 as an Integrated Development Team Lead. Oversaw 20+ Process Scientists to deliver numerous development programs spanning pre-clinical through launch. Drove development strategy/implementation of development assets from pre-clinical to launch, including small molecule, antibody drug conjugate, vitamin drug.
Oct 2004 - Oct 2007
3 education records
Robert Discordia, Phd education
Post Doctoral, Organic Chemistry
Scripps Research
Ph.D., Organic Chemistry
Syracuse University
Bs, Chemistry
State University Of New York Cortland
FAQ
Frequently asked questions about Robert Discordia, Phd
Quick answers generated from the profile data available on this page.
What company does Robert Discordia, Phd work for?
Robert Discordia, Phd works for EQUULUS Therapeutics.
What is Robert Discordia, Phd's role at EQUULUS Therapeutics?
Robert Discordia, Phd is listed as Co-Founder, President and CEO at EQUULUS Therapeutics.
What is Robert Discordia, Phd's email address?
AeroLeads has found 1 work email signal at @juno.com for Robert Discordia, Phd at EQUULUS Therapeutics.
What is Robert Discordia, Phd's phone number?
AeroLeads has found 5 phone signal(s) with area code 609, 732, 212 for Robert Discordia, Phd at EQUULUS Therapeutics.
Where is Robert Discordia, Phd based?
Robert Discordia, Phd is based in Charlotte, North Carolina, United States while working with EQUULUS Therapeutics.
What companies has Robert Discordia, Phd worked for?
Robert Discordia, Phd has worked for Equulus Therapeutics, Caamtech, Avanzarx, Corbus Pharmaceuticals, and Bristol Myers Squibb.
How can I contact Robert Discordia, Phd?
You can use AeroLeads to view verified contact signals for Robert Discordia, Phd at EQUULUS Therapeutics, including work email, phone, and LinkedIn data when available.
What schools did Robert Discordia, Phd attend?
Robert Discordia, Phd holds Post Doctoral, Organic Chemistry from Scripps Research.
What skills is Robert Discordia, Phd known for?
Robert Discordia, Phd is listed with skills including R&D, Pharmaceutical Industry, Technology Transfer, Drug Development, Validation, Gmp, Organic Synthesis, and Pharmaceutics.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial